This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Quarter ended Sep 2026: consolidated revenue up 21%, profit after tax up 30% year on year
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Midcap 150 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations rose 20.8% to Rs 118,357 lakh from Rs 97,994 lakh a year earlier, while profit after tax rose 30.4% to Rs 33,588 lakh from Rs 25,749 lakh. Other income included Rs 4,209 lakh of interest on an income-tax refund. For the consolidated six months ended 30 September 2026, revenue was Rs 212,201 lakh and profit after tax Rs 57,306 lakh. The limited review was unmodified.
Revenue and profit growth supports sentiment, but the Rs 4,209 lakh tax-refund interest is non-recurring, so earnings quality is mixed.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,184 Cr | ₹979.9 Cr | +20.8% |
| Operating profit | ₹386.6 Cr | ₹317.8 Cr | +21.6% |
| Profit after tax | ₹335.9 Cr | ₹257.5 Cr | +30.4% |
| EBITDA margin | 34.0% | 34.5% | −0.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.